Biogen Raises 2026 Profit Outlook as Leqembi Sales Accelerate
Biogen forecast 2026 profit above Wall Street estimates, citing strong demand for its Alzheimer’s treatment Leqembi as older multiple sclerosis therapies face pricing pressure from cheaper alternatives. The company expects Leqembi revenue to offset continued declines across its broader portfolio in the coming year.
1. Profit Forecast Exceeds Estimates
Biogen announced it expects 2026 adjusted profit to surpass analysts’ consensus, banking on growth in its Alzheimer’s franchise. This outlook reflects management’s confidence in Leqembi performance despite headwinds in its legacy multiple sclerosis business.
2. Leqembi Sales Drive Growth
The company cited accelerating uptake of Leqembi as the primary catalyst, noting stronger-than-expected prescriptions and pricing resilience. Biogen plans to leverage this momentum to stabilize overall revenue as older branded MS therapies continue to face generic competition.